Alma STANCU

Passionate Medical Oncologist at Institut Sainte Catherine, Avignon, France.
Thoracic Oncologist and Lung Cancer Advocacy.

[Maxime Patout @maximepatout]

@ThomasFatome @Assur_Maladie il ne manquerait pas la prévention par les professionnels en charge du premier cancer en France (à tout hasard les pneumologues, cancer du poumon) @SPLF_SocPneumo @s_couraud @DrGonzalezJesus sans compter toutes les maladies liées au #tabac un oubli??

[Alma STANCU @StancuAlma]

@s_couraud Incroyable!!

[Alma STANCU @StancuAlma]

@said78t @AlkRos1France @delairasso On a jamais dit le contraire ! Et vous venez avec un message fort pour le autres patients aussi!

[Alma STANCU @StancuAlma]

On a pu rencontrer nos patient grâce à notre réunion "Vivre avec un cancer du poumon!" à Avignon! Une première dans notre région! #institutsaintecatherine #cancerpoumon @delairasso @AlkRos1France

[Bilal Piperdi @bpiperdi]

For pts who are lucky enough to complete 2-yr of pembro, 3 yr from STOPPING treatment, 70% chance of being alive & ~45% chance of not needing any other treatment for lung cancer! Not something I thought I’ll be able to tell my pts when I started my career! #LCSM #esmo22

[Stephen V Liu, MD @StephenVLiu]

Happening now at the @IASLC #NACLC22 meeting (and virtually) - a discussion about antibody drug conjugates for lung cancer with Drs. @marinagarassino @HosseinBorghaei and me. Come join the conversation in this free @PeerView #CME event. Registration link:

https://t.co/e6eOpbBjux

[H. Jack West, MD, FASCO @JackWestMD]

#AILCC22 @DrJNaidoo highlights debatable role of ICI monotherapy vs/chemo-immunotherapy for pts w/high PD-L1, noting that @flatironhealth data show no difference in OS. Data are in eye of the beholder, but no clear incentive to favor "more is better" from this work. #LCSM

[Sébastien Couraud 🫁🚭🌍 @s_couraud]

🚨🚨🚨🚨🚨
En raison du départ en retraite prochain de @souquet_pj 😪, nous nous mettons en recherche de notre futur(e) collègue @pneumo_LS 😉!
Nous cherchons donc un(e) PH de pneumologie temps plein pour l'été 2023 !
N'hésitez pas à candidater !

[Mariana Brandao @MarianaBrandao0]

Beautiful talk by Dr Fátima Cardoso while receiving the @myESMO Women for Oncology Award 2022 🙏
We should actively work to end the #gendergap & to improve women's rights around the world. We should #speakup & maybe do some conscious bias from time to time :)
@OncoAlert #ESMO22

[European Code Against Cancer @cancercode]

👉🏽Want to become a certified #cancerprevention promoter?

Try @IARCWHO's #CPElearning about the #cancercode in 🇬🇧 🇫🇷: https://t.co/IN9y9no0We

✍🏽Register: https://t.co/Ql429TT81x

📲Spread the word: https://t.co/4ZwfHIuGSb

[IASLC @IASLC]

Apply today for the @IASLC Academy— a global development program for early-career physicians pursuing academic careers in thoracic oncology. Participants receive mentoring & explore topics about career dev & research. Applications open until 10/3 at https://t.co/Q69Q9MCrif #LCSM

[FabriceAndre @FAndreMD]

The presentation: "Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study" has just been added to the Presidential session III of #ESMO2022 First randomized trial testing a KRAS inhibitor in NSCLC

[European Code Against Cancer @cancercode]

🔸Make your home #smokefree
🔸Support smoke-free policies
in your #workplace

🚫Exposure to second-hand smoke is associated with avoidable illness, including #cancer.

👉🏽https://t.co/SpaMZ5uk6i

[Jorge Alatorre Alexander @JorgeAlatorreA1]

Interesting review of #updates on #treatments and #diagnostic methods for #non-small cell #lungcancer.🫁
https://t.co/sCHB2EHnBw

[Melina Marmarelis @MMarmarelis]

MET amp most common resistance mechanism within 1st yr post osi. Amps in ctdna hard to interpret but this tracks clinically. Best way to identify MET mech of resistance? I prefer IHC 2/2 ami/laz data, you? #WCLC22 @iaslc @StephenVLiu @JackWestMD
@CharuAggarwalMD

[Janet Freeman-Daily @JFreemanDaily]

2022-08-16 Updated chart of Biomarker-focused patient-caregiver groups. #LCSM @ros1cancer @ALKLungCancer @Exon20Group @EGFRResisters @RetRenegades @alk_fusion @KRASKickers @NTRKers @metcrusaders @BrafBombers @RETpositive

[Alma STANCU @StancuAlma]

@onco_aura 2022,non?

[The Lancet Oncology @TheLancetOncol]

Online first: #Sintilimab plus #bevacizumab #biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell #lungcancer #NSCLC who progressed on EGFR TKI therapy: first interim results from ORIENT-31 https://t.co/5VwmLCcGW5

[Dispositif Spécifique Régional du Cancer @OncoPacaCorse]

FORMATION RÉFÉRENT PARCOURS ONCOFERTILITÉ I📅Jeudi 24.11.22
📍The Camp, Aix-en-Provence
🎯Professionnels de santé : médecins et soignants souhaitant devenir "Référent Parcours Oncofertilité de leur établissement" & membres des cellules 3C et autres professionnels intéressés 👇

[Clinical Lung Cancer @ClinicalLung]

A real-world, retrospective study published @ClinicalLung shows that ICI therapy may be less effective for patients with EGFR exon 20 insersion positive NSCLC compared with wild type-NSCLC.

Read more: https://t.co/zCKEgPRJ4x